Data from https://swaggystocks.com/dashboard/wallstreetbets/ticker-sentiment
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/21/2024 | $145.00 → $160.00 | Overweight | Barclays | |
| 11/21/2024 | $155.00 → $170.00 | Overweight | Analyst | |
| 11/21/2024 | $150.00 → $165.00 | Buy | Goldman | |
| 11/21/2024 | $165.00 → $185.00 | Overweight | Wells Fargo | |
| 11/21/2024 | $167.00 → $169.00 | Buy | Truist | |
| 11/21/2024 | $150.00 → $190.00 | Outperform | Robert W. Baird | |
| 11/21/2024 | $170.00 → $190.00 | Buy | The Benchmark Company | |
| 11/21/2024 | $189.00 → $190.00 | Outperform | Evercore ISI |
SC 13G/A - Palantir Technologies Inc. (0001321655) (Subject)
SC 13G/A - Robinhood Markets, Inc. (0001783879) (Subject)
SC 13G/A - Robinhood Markets, Inc. (0001783879) (Subject)
Barclays reiterated coverage of NVIDIA with a rating of Overweight and set a new price target of $160.00 from $145.00 previously
Analyst reiterated coverage of NVIDIA with a rating of Overweight and set a new price target of $170.00 from $155.00 previously
Goldman reiterated coverage of NVIDIA with a rating of Buy and set a new price target of $165.00 from $150.00 previously
4 - Walt Disney Co (0001744489) (Issuer)
4 - Walt Disney Co (0001744489) (Issuer)
4/A - Robinhood Markets, Inc. (0001783879) (Issuer)
For Immediate Release: September 17, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a draft guidance, “Integrating Randomized Controlled Trials for Drug and Biological Products into Routine Clinical Practice,” which, when finalized, will support the conduct of randomized controlled trials with streamlined protocols a
For Immediate Release: September 12, 2024 Today, the U.S. Food and Drug Administration authorized the first over-the-counter (OTC) hearing aid software device, Hearing Aid Feature, intended to be used with compatible versions of the Apple AirPods Pro headphones. Once installed and customized to the user’s hearing needs, the Hearing Aid Feature enables compatible versions of the AirPods Pro to serve as an OTC hea
Former FDA deputy commissioner and former Pfizer & Hillrom quality executive join Hims & Hers, deepening the leadership that drives the company's high standard of quality and safety Hims & Hers Health, Inc. ("Hims & Hers") (NYSE:HIMS), the leading health and wellness platform, today announced Deb Autor, former deputy commissioner at the FDA, will join the company's board of directors, and Janet Stevens, a pharmaceutical quality expert, will join the company as Global Head of Quality & Safety. Hims & Hers continues to prioritize safety across its platform, offerings, and leadership so that every customer can have the confidence that the solutions they have access to are safe, high-quality,
NEW YORK, Nov. 1, 2024 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the Dow Jones Industrial Average (DJIA) and Dow Jones Utility Average (DJUA) effective prior to the open of trading on Friday, November 8: NVIDIA Corp. (NASD:NVDA) will replace Intel Corp. (NASD:INTC), and The Sherwin-Williams Co. (NYSE:SHW) will replace Dow Inc. (NYSE:DOW) in the Dow Jones Industrial Average. The index changes were initiated to ensure a more representative exposure to the semiconductors industry and the materials sector respectively. The DJIA is a price weighted index, and thus persistently lower priced stocks have a minimal impact on the index. Dow Inc. is also the smallest com
The former Fortune 50 CEO joins Define to further drive transformational change in healthcare at the earliest stages of innovation SAN FRANCISCO, Oct. 22, 2024 /PRNewswire/ -- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today announced that Bruce Broussard, former CEO and president of Humana (NYSE:HUM), has joined the firm as venture partner. Bruce will play a pivotal role at Define, leveraging his invaluable experience scaling companies and fostering innovation within private startups, mid-size companies, and the Fortune 50. He will partner closely with Define founders to scale their businesses and become category-defining companie
SANTA CLARA, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- NVIDIA will present at the following events for the financial community: UBS Global Technology and AI ConferenceTuesday, Dec. 3, 6:35 a.m. Pacific time J.P. Morgan Healthcare ConferenceMonday, Jan. 13, 9:45 a.m. Pacific time Interested parties can listen to the live audio webcast of NVIDIA financial presentations at investor.nvidia.com. Webcast replays are available for 90 days afterward. About NVIDIANVIDIA (NASDAQ:NVDA) is the world leader in accelerated computing. For further information, contact: NVIDIA Investor RelationsNVIDIA Corporate [email protected]@nvidia.com © 2024 NVIDIA Corporation. All rights reserv
Continuing to strengthen its comprehensive weight loss offerings, Hims & Hers' addition of daily meal replacement bars and shakes is the company's latest step in helping its customers reach – and maintain – their health and wellness goals Hims & Hers Health, Inc. (("Hims &, Hers", NYSE:HIMS), the leading health and wellness platform, today announced that Hims & Hers customers will now be able to supplement their treatment plan with daily meal replacement bars and shakes to support them on their comprehensive weight loss journey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241121849741/en/To help its customers stay on top of
Record quarterly revenue of $35.1 billion, up 17% from Q2 and up 94% from a year agoRecord quarterly Data Center revenue of $30.8 billion, up 17% from Q2 and up 112% from a year ago SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- NVIDIA (NASDAQ:NVDA) today reported revenue for the third quarter ended October 27, 2024, of $35.1 billion, up 17% from the previous quarter and up 94% from a year ago. For the quarter, GAAP earnings per diluted share was $0.78, up 16% from the previous quarter and up 111% from a year ago. Non-GAAP earnings per diluted share was $0.81, up 19% from the previous quarter and up 103% from a year ago. "The age of AI is in full steam, propelling a global
Record quarterly revenue of $35.1 billion, up 17% from Q2 and up 94% from a year agoRecord quarterly Data Center revenue of $30.8 billion, up 17% from Q2 and up 112% from a year ago SANTA CLARA, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- NVIDIA (NASDAQ:NVDA) today reported revenue for the third quarter ended October 27, 2024, of $35.1 billion, up 17% from the previous quarter and up 94% from a year ago. For the quarter, GAAP earnings per diluted share was $0.78, up 16% from the previous quarter and up 111% from a year ago. Non-GAAP earnings per diluted share was $0.81, up 19% from the previous quarter and up 103% from a year ago. "The age of AI is in full steam, propelling a global
The Walt Disney Company (NYSE:DIS) today reported earnings for its fourth quarter and full year ended September 28, 2024. Financial Results for the Quarter and Full Year: Revenues increased 6% for Q4 to $22.6 billion from $21.2 billion in the prior-year quarter, and 3% for the year to $91.4 billion from $88.9 billion in the prior year. Income before income taxes declined 6% to $0.9 billion in Q4 from $1.0 billion in the prior-year quarter and increased 59% for the year to $7.6 billion from $4.8 billion in the prior year. Diluted earnings per share (EPS) for Q4 increased 79% to $0.25 from $0.14 in the prior-year quarter, and for the year more than doubled to $2.72 from $1.29 in th
Revenue of $401.6 million, up 77% year-over-year in Q3 2024 Net income of $75.6 million; Adjusted EBITDA of $51.1 million in Q3 2024 Subscribers grew to 2.0 million, up 44% year-over-year in Q3 2024 Raises full year 2024 revenue guidance to a range of $1.460 billion to $1.465 billion and Adjusted EBITDA guidance to a range of $173 million to $178 million Hims & Hers Health, Inc. (("Hims &, Hers" or the "Company", NYSE:HIMS), the leading health and wellness platform, today announced financial results for the third quarter ended September 30, 2024 in a shareholder letter that is posted at investors.hims.com. "Improving momentum in both the Hims and Hers brands delivered another strong qu
8-K - Hims & Hers Health, Inc. (0001773751) (Filer)
10-Q - NVIDIA CORP (0001045810) (Filer)
8-K - NVIDIA CORP (0001045810) (Filer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
4 - Walt Disney Co (0001744489) (Issuer)
4 - Hims & Hers Health, Inc. (0001773751) (Issuer)
To gain an edge, this is what you need to know today. GDP Brings Buying Please click here for an enlarged chart of Invesco QQQ Trust Series 1 (NASDAQ:QQQ). Note the following: The chart shows a drop in QQQ. The drop in QQQ was triggered by speculative sentiment pulling back. As a reader of The Arora Report, you knew in advance that speculative sentiment could fall as a result of Tesla Inc (NASDAQ:TSLA) earnings. The chart shows that QQQ is approaching the support zone. RSI on the chart shows that QQQ is now oversold. Oversold markets tend to bounce. The chart shows that the volume was low on the selloff. This indicates a lack of conviction in selling. Especially hard hit in
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Baird increased Apple Inc. (NASDAQ:AAPL) price target from $200 to $240. Baird analyst William Power maintained an Outperform rating. Apple shares fell 0.1% to trade at $218.51 on Thursday. See how other analysts view this stock. Truist Securities raised the price target for ServiceNow, Inc. (NYSE:NOW) from $750 to $780. Truist Securities analyst Joel Fishbein maintained a Hold rating. ServiceNow shares gained 11.9% to trade at $817.75 on Thursday. See how other analysts view this stock. JP Morg
Honda Motor Co. (NYSE:HMC) will reduce its production of gasoline vehicles in China by 19% starting this October, marking a strategic shift toward electric vehicles. The Japanese automaker will cease operations of one production line at its joint venture Dongfeng Honda, which has an annual capacity of 240,000 units, beginning in November. Additionally, in October, GAC Honda, another of its facilities with a capacity of 50,000 units annually, will be completely shut down. These changes are part of Honda's effort to accelerate the “steady shift” to EVs, reported Bloomberg. Honda’s production capacity in China, currently around 1.5 million units, will see a reduction of 19% due to